Titratable Control of blood pressure reduction with CLEVIPREX® (clevidipine)
CLEVIPREX—a dihydropyridine calcium channel blocker—can provide blood pressure (BP) reduction in the perioperative setting and in acute severe hypertension cases.
Non–weight-based dosing regimen that is independent of renal or hepatic function1
CLEVIPREX is a low-volume, non–weight-based dosing regimen for individualized, titratable administration.1Calculate Dosing
Proven efficacy in clinical studies
- Over 90% of patients with perioperative hypertension achieved treatment success (≥15% BP reduction from baseline)2,3
- Low rate of overshoot in acute severe hypertension patients in the VELOCITY trial4
BP reduction within minutes
In perioperative patients, CLEVIPREX produces a 4%–5% reduction in systolic blood pressure (SBP) within 2–4 minutes of initiation. An approximately 1–2 mg/hr increase will generally produce an additional 2–4 mmHg decrease in systolic pressure.
Demonstrated safety profile
The safety profile of CLEVIPREX was evaluated in multiple clinical trials.1